Vamorolone

Introduction Overview

Generic Name

vamorolone

Brand Name

Agamree

Dosage Form

oral suspension (40 mg/mL)

Drug Class

Glucocorticoids

Pharmacokinetics

Absorption:
Vamorolone is administered orally as an oral suspension and exhibits good gastrointestinal absorption. The bioavailability is optimized when taken with a meal, as food intake can influence the rate of absorption. Clinical data suggest that the drug’s oral suspension formulation allows for consistent plasma concentrations suitable for once-daily dosing. Specific pharmacokinetic parameters such as peak plasma concentration (Cmax), time to peak concentration (Tmax), and absolute bioavailability, however, remain to be fully characterized in extensive post-marketing studies, though clinical trials indicate effective systemic exposure necessary for therapeutic action.

Distribution:
Once absorbed, vamorolone distributes throughout body tissues, particularly where inflammation is present. As a glucocorticoid, vamorolone crosses cell membranes easily and binds to intracellular glucocorticoid receptors. Distribution volume is expected to be moderate, similar to other corticosteroids, allowing penetration into inflamed muscle fibers impacted by Duchenne muscular dystrophy (DMD). It is highly plasma-protein bound, mainly to albumin and corticosteroid-binding globulin (CBG). Cerebrospinal fluid penetration is limited but sufficient to exert systemic corticosteroid effects without pronounced central nervous system side effects.

Metabolism:
Vamorolone undergoes hepatic metabolism primarily via cytochrome P450 enzymes, predominantly CYP3A4. The metabolic pathways likely include reduction, hydroxylation, and conjugation reactions characteristic of steroid metabolism. The drug's metabolism may be influenced by hepatic function, with mild to moderate hepatic impairment necessitating dose adjustments. Co-administration with strong CYP3A4 inhibitors such as itraconazole significantly increases vamorolone plasma levels, requiring dosage modification to avoid toxicity.

Elimination:
The elimination of vamorolone is primarily renal and possibly fecal excretion of metabolites. The drug has a half-life suitable for once daily dosing, ensuring sustained therapeutic levels. The elimination clearance can be altered in patients with impaired liver function due to modified metabolism. Dose adjustments are recommended for patients with hepatic impairment to prevent accumulation. There is limited renal excretion of unchanged drug, reducing concern for renal clearance variability. Clinical data confirm steady-state pharmacokinetics, supporting the safety and efficacy profile in pediatric patients with DMD.

Dosage Forms

Available Dosage Forms:
Vamorolone is currently available as a 40 mg/mL oral suspension, marketed under the brand name Agamree. This formulation facilitates dosing accuracy in pediatric patients and populations requiring weight-based dosing. The oral suspension includes inactive ingredients such as citric acid (monohydrate), disodium phosphate, glycerin, hydrochloric acid (for pH adjustment), orange flavor, sodium benzoate, sucralose, water, and xanthan gum, which enhance palatability and stability.

Dosages for Adults and Adolescents:
Vamorolone is FDA-approved for patients aged 2 years and older with Duchenne muscular dystrophy. The usual dose is 6 mg/kg orally once daily, preferably with a meal, with dosing capped at a maximum of 300 mg per day for patients weighing over 50 kg. In patients with mild to moderate hepatic impairment, the recommended dose is reduced to 2 mg/kg once daily, up to a maximum of 100 mg daily for those above 50 kg. When combined with strong CYP3A4 inhibitors, the dose is adjusted to 4 mg/kg once daily, with a max of 200 mg daily for heavier patients.

Specific Patient Populations:
Pediatric patients with DMD are the primary population treated with vamorolone; dosage and administration are weight-based. Dose tapering is crucial when extending therapy beyond one week to prevent adrenal insufficiency. There is a lack of data for use in pregnancy and breastfeeding, and use should be cautious considering potential risks. Elderly and patients with hepatic or renal impairment require dose adjustments. The oral suspension form allows for flexible dosing adjustments in these populations. Patients with compromised liver function require lower doses to reduce risk of accumulation and side effects.

Mechanism Of Action

Vamorolone functions primarily through binding to the glucocorticoid receptor (GR), a ligand-activated transcription factor expressed in various tissues including muscle, immune cells, and the central nervous system. Upon binding, vamorolone activates GR-mediated signaling pathways that regulate gene expression leading to potent anti-inflammatory and immunosuppressive effects. Unlike classical corticosteroids, vamorolone has a dissociative nature allowing separation of anti-inflammatory effects from some typical glucocorticoid adverse effects.

At the molecular level, vamorolone modulates the production of pro-inflammatory cytokines by inhibiting transcription factors such as NF-κB and AP-1, reducing the expression of interleukins, tumor necrosis factor-alpha (TNF-α), and other mediators responsible for muscle inflammation and damage in Duchenne muscular dystrophy (DMD). Additionally, vamorolone stabilizes muscle membranes and reduces muscle degeneration and fibrosis through yet not fully elucidated pathways distinct from traditional steroids.

Cellularly, vamorolone’s selective receptor modulation results in reduced activation of mineralocorticoid receptors, leading to potentially fewer side effects related to sodium retention and hypokalemia. Studies have shown preservation of bone health, growth, and neurobehavioral profiles compared to prednisone and deflazacort, implicating a favorable side effect profile associated with its unique receptor interaction.

Clinically, vamorolone improves motor function and muscle strength in boys with DMD by attenuating inflammatory processes that contribute to muscle breakdown and by modulating immune responses. Unlike traditional glucocorticoids, clinical trials such as VISION-DMD demonstrated vamorolone’s efficacy in improving clinical parameters while exhibiting fewer effects on growth suppression, weight gain, and behavioral disturbances. Current research supports vamorolone as a next-generation corticosteroid with an improved benefit-risk profile for chronic inflammatory neuromuscular disorders.

Pharmacological Actions

Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive properties.
Inhibition of pro-inflammatory cytokine production, including TNF-α and interleukins.
Dissociative modulation of glucocorticoid receptor allowing reduced mineralocorticoid receptor activity.
Reduction of muscle inflammation and fibrosis in Duchenne muscular dystrophy.
Suppression of immune system reducing autoimmune and inflammatory processes.
Stabilization of muscle cell membranes to reduce damage.
Improvement of motor function by preserving muscle integrity.
Potential bone-sparing effects compared to classical corticosteroids.
Mitigation of typical corticosteroid-associated adverse effects such as growth suppression and behavioral changes.
Modulation of gene transcription affecting multiple inflammatory pathways.
Selective receptor interaction minimizing water and sodium retention effects.
Dampening of NF-κB and AP-1 transcription factors involved in inflammation.
Decrease in adrenal hormone overproduction through dose-dependent steroid receptor activity.
Reduction in acute phase reactants and inflammatory markers in systemic circulation.
Immunosuppressive effects that reduce susceptibility to inflammatory exacerbations.

Therapeutic Or Clinical Uses

Treatment of Duchenne muscular dystrophy (DMD) to improve motor function.
Reduction of muscle inflammation associated with progressive neuromuscular disorders.
Immunosuppressive agent to modulate aberrant immune responses in DMD.
Alternative corticosteroid option with fewer side effects for long-term management of DMD.
Improvement of muscle strength and endurance in pediatric DMD patients.
Potential use in other inflammatory or autoimmune conditions requiring glucocorticoids (off-label).
Management of chronic inflammation and immune modulation in corticosteroid-responsive diseases.
Reduction of muscle fibrosis progression associated with muscular dystrophy.
Used in patients with contraindications or intolerance to conventional corticosteroids.
Adjunctive therapy to maintain growth velocity and bone health during corticosteroid treatment.
Modification of inflammatory milieu in neuromuscular and systemic autoimmune disorders.
Treatment of corticosteroid-responsive conditions where preservation of quality of life is priority.
Prevention of deterioration of muscle function in progressive muscular diseases.
Therapeutic option for pediatric patients needing corticosteroid treatment with improved safety profile.
Clinical benefit supported by FDA approval following positive outcomes in randomized clinical trials.

Side Or Adverse Effects

Vomiting
Weight gain
Psychiatric disorders including mood changes, depression, anxiety
Vitamin D deficiency
Cushingoid features (thin limbs, moon face, fat accumulation around neck and shoulders, stretch marks)
Increased susceptibility to infections including opportunistic viral, bacterial, fungal infections
Signs of allergic reaction such as hives, facial swelling, or difficulty breathing
Potential adrenal insufficiency upon abrupt withdrawal
Hypokalemia and hypocalcemia leading to muscle cramps and cardiac arrhythmias
Hyperglycemia and increased risk or worsening of diabetes mellitus
Skin lesions ranging from mild rashes to severe dermatological reactions
Growth retardation or decreased growth rate in pediatric patients
Gastrointestinal side effects including risk for perforation especially with pre-existing GI disorders
Mood or behavioral changes including irritability, agitation, panic attacks, suicidal ideation
Muscle weakness or musculoskeletal pain potentially aggravated with long-term use

Precautions

Avoid abrupt discontinuation; taper dose gradually to prevent adrenal insufficiency.
Monitor patients closely for infections due to immunosuppressive effects.
Assess growth and development regularly in pediatric patients during therapy.
Use cautiously in patients with pre-existing diabetes or risk factors for hyperglycemia.
Avoid live vaccines 4 to 6 weeks prior to and during treatment due to immunosuppression.
Monitor blood pressure and electrolyte levels due to risk of hypertension and hypokalemia.
Caution in patients with gastrointestinal ulcers or disorders due to increased perforation risk.
Avoid exposure to chickenpox and measles; vaccinate appropriately before starting therapy.
Regular ophthalmologic exams recommended to detect cataracts or glaucoma.
Evaluate thyroid function as hypo- or hyperthyroidism may alter vamorolone clearance.
Use with caution in patients with pheochromocytoma due to risk of crisis.
Assess mood and behavioral symptoms frequently; advise caregivers to report sudden changes.
Monitor bone health; consider supplementation or prophylaxis for osteoporosis.
Use lowest effective dose for shortest duration to minimize side effects.
Inform patients and caregivers about signs of blood clots and instruct to seek emergent care if suspected.

Warnings

Do not abruptly stop therapy; risk of adrenal insufficiency crisis.
Increased risk of serious and potentially fatal infections due to immunosuppression.
Hyperglycemia risk requiring monitoring especially in diabetics.
Potential for gastrointestinal perforation in patients with diverticulitis or ulcers.
Contraindicated in patients allergic to vamorolone or formulation components.
Live vaccines contraindicated during and shortly before treatment.
Monitor for pheochromocytoma crisis in susceptible patients.
Long-term use may impair growth and development in pediatric patients.
Risk of blood clots including deep vein thrombosis and pulmonary embolism.
May precipitate or worsen psychiatric disorders such as depression or mania.
Potential adrenal gland hormone imbalance symptoms including Cushing's syndrome.
Can cause ocular side effects such as cataracts and glaucoma with prolonged use.
Use caution with concomitant drugs that affect CYP3A4 metabolism and vitreoretinal status.
Pregnancy use only if benefits justify potential fetal risks; monitor neonates for hypoadrenalism.
Breastfeeding considerations given potential corticosteroid excretion into human milk.

Contraindication

Known hypersensitivity or allergy to vamorolone or any inactive ingredients in the formulation.
Active untreated infections including systemic bacterial, fungal, or viral infections.
Patients receiving live or live-attenuated vaccines during the course of therapy.
Caution or contraindication in patients with existing gastrointestinal perforation or at high risk.
Severe uncontrolled diabetes mellitus or hypertension without adequate management.
Untreated or poorly controlled pheochromocytoma due to risk of hypertensive crisis.
Patients with systemic fungal infections due to immunosuppression.
History of severe psychiatric disorders unresponsive to medical management.
Patients with recent major surgery requiring immunological competence.
Severe hepatic impairment without capacity for dose adjustment and monitoring.
Known blood clotting disorders unless benefits outweigh risks and monitoring is feasible.
Patients who have recently received certain vaccines without appropriate timing to avoid interactions.
Pediatric patients with contraindications to corticosteroids other than DMD indication.
Patients with glaucoma or cataracts requiring ongoing ophthalmological assessment.
Pregnant women unless clinically justified, given limited safety data.

Drug Interactions

Strong CYP3A4 inhibitors such as itraconazole increase vamorolone plasma concentrations, requiring dose reduction.
Co-administration with other immunosuppressants may potentiate infection risk.
Non-steroidal anti-inflammatory drugs (NSAIDs) may increase risk of gastrointestinal ulceration.
Antidiabetic medications may have reduced efficacy due to hyperglycemic effects of vamorolone.
Vaccines, particularly live-attenuated vaccines, may have reduced effectiveness or increased risk of infection.
Potassium depleting diuretics increase risk of hypokalemia when combined with vamorolone.
Anticoagulants interaction may alter bleeding risk due to corticosteroid effects on coagulation.
Drugs affecting electrolytes, such as digoxin, may have altered effectiveness due to cortisol-induced electrolyte changes.
Phenytoin and other enzyme-inducing anticonvulsants may decrease vamorolone levels.
Hepatotoxic drugs may increase hepatic burden when used concomitantly.
Oral contraceptives may have altered effectiveness due to corticosteroid-induced hepatic enzyme modulation.
Live vaccines contraindicated during therapy due to immunosuppression.
Interactions with herbal supplements such as St. John's Wort may reduce vamorolone efficacy.
Simultaneous use with QT-prolonging agents may increase cardiac arrhythmia risk via electrolyte disturbances.
Methotrexate toxicity may be enhanced when combined with glucocorticoids.

Preparations Of The Drug

40 mg/mL oral suspension (Agamree brand) for pediatric and adult dosing flexibility.
Formulated with citric acid monohydrate, disodium phosphate, glycerin, and xanthan gum as stabilizers and viscosity enhancers.
Hydrochloric acid used for pH adjustment to maintain suspension stability and bioavailability.
Contains sodium benzoate and sucralose to provide preservative effect and palatability respectively, improving patient compliance.
Orange flavoring added to enhance acceptability in pediatric patients.
Available in bottles with an enclosed oral syringe for precise dosing.
Storage instructions specify room temperature before opening and refrigeration (2°C to 8°C) after opening to maintain stability.
Shelf life post-opening limited to 3 months to ensure potency and safety.
Shaking required for 30 seconds before administration to ensure uniform suspension.
Manufactured by Santhera Pharmaceuticals (USA), Inc., Burlington, MA.
Packaging includes detailed patient instructions and warnings to ensure safe administration.
No tablet or capsule formulations available currently, focusing on oral suspension form for dose accuracy.
The preparation is free from common allergens such as gluten or lactose.
Formulated for once-daily dosing to improve adherence in chronic treatment.
Excipients selected for minimal systemic absorption and low allergic potential.